

Duration of untreated illness in panic disorder: a poor outcome risk factor?

A Carlo Altamura
Annalisa Santini
Daniele Salvadori
Emanuela Mundo

Department of Psychiatry,
Department of Clinical Sciences
"Luigi Sacco", University of Milan,
Milan, Italy

Objective: The aim of this naturalistic study was to evaluate the impact of the duration of untreated illness (DUI) on the outcome and treatment response of panic disorder (PD).

Methods: Ninety-six outpatients with PD who underwent an 8-week open-label treatment with serotonergic antidepressants were subdivided into two subgroups: those with $\text{DUI} \leq 1$ year and those with $\text{DUI} > 1$ year. The main baseline demographic and clinical variables were calculated and compared between the two subgroups of patients (chi-square test or t-test for independent samples). The effect of the antipanic medication was evaluated by analysis of variance with repeated measures considering Hamilton Rating Scale for Anxiety, Clinical Global Impression rating scores, and the number of panic attacks/week as the dependent variables (outcome measures), while the subgroups were the independent ones. Comorbidity with onset later than PD was also considered.

Results: There were no differences between patients with $\text{DUI} \leq 1$ year and patients with $\text{DUI} > 1$ year with respect to the outcome measures considered. However, patients with $\text{DUI} > 1$ year ($N=64$) had a higher frequency of comorbid major depressive disorder (MDD) with onset later than PD ($p=0.006$).

Conclusions: Results from this study suggest that the DUI may be a predictor of the development of comorbid MDD in PD. Further investigations on larger samples and with longer follow-up are warranted.

Keywords: panic disorder, duration of untreated illness, treatment, outcome

Introduction

Panic disorder (PD) is considered a chronic and debilitating illness characterized by recurrent, severe, and spontaneous anxiety attacks accompanied by a wide variety of autonomic symptoms (Dannon et al 2004). Some population-based epidemiological studies showed that approximately 15% of subjects experience isolated panic attacks and up to 3.8% develop full-syndromal PD during the course of their life (Eaton et al 1994).

PD is often comorbid with other psychiatric disorders such as bipolar disorder, major depressive disorder (MDD), and other anxiety disorders (Diler et al 2004; Westenberg et al 2004). In addition, PD is associated with a significant impact on global functioning and quality of life (Starcevic et al 1993; Carpiniello et al 2002). The functional disability and risk of suicidal ideation and behavior associated with comorbid panic and depression far exceed those associated with either disorder alone (Markowitz et al 1989; Goodwin et al 2001). Recently, Bittner et al (2004) suggested that anxiety disorders (including panic disorder) act as risk factors for the first onset of MDD. Furthermore, the presence of several clinical characteristics of anxiety disorders (eg, specific phobia, social phobia, panic disorder, agoraphobia, and generalized anxiety disorder), and the presence of more than one anxiety disorder with severe impairment of global functioning appear to play a substantial role in determining the susceptibility to MDD.

Correspondence: A Carlo Altamura
Department of Clinical Sciences "Luigi
Sacco", University of Milan, Via GB
Grassi 74, 20157 Milan, Italy
Tel +39 02 3904 2904
Fax +39 02 3904 2510
Email c.altamura@hsacco.it

Although several effective pharmacological treatments do exist for PD, up to 20%–40% of patients can be considered nonresponders to pharmacotherapy, thus accounting for most of the individual and society costs associated with the illness (Slaap and den Boer 2001). Some clinical variables have been most consistently identified as predictors of poor outcome in PD: panic severity, presence of agoraphobia, comorbid depression, comorbid personality disorder, duration of illness, and female gender (Pollack et al 2000).

Duration of untreated illness (DUI), defined as the time elapsing from the onset of an illness and the first adequate treatment, has been considered an important predictive variable for the course of some psychiatric disorders such as schizophrenia (Altamura et al 2001). However, the role of the DUI in mood disorders is still controversial (Craig et al 2000; Mundo et al 2002). Only few studies exist on the possible association between a longer DUI and a poorer outcome in PD (Scheibe and Albus 1997; Katscing et al 1998; Shinoda et al 1999).

The primary aim of this study was to evaluate the impact of the DUI on the course and the pharmacological treatment response in PD.

Methods

This naturalistic study included 96 patients (26 males and 70 females) with PD, with or without agoraphobia, diagnosed by a semistructured psychiatric interview based on DSM-IV criteria, and treated with SSRIs, venlafaxine or clomipramine. Treatment was chosen and administered by the treating psychiatrists at flexible doses, adjusted according to clinical needs and tolerability. For the 8-week study duration no concomitant treatment (pharmacological or nonpharmacological) was allowed except for previously stabilized doses of benzodiazepines (not exceeding 5 mg diazepam eq/day). After a complete description of the study, written informed consent to participate was obtained from all subjects.

At baseline, the following clinical variables were collected: age, age at onset, DSM-IV Axis I diagnoses, family history (FH) for anxiety or mood disorders in first-degree relatives, and the duration of untreated illness (DUI) defined as the interval (months) between the onset of PD and the first adequate (considering time and doses) antipanic pharmacological treatment.

Data on the DUI were collected using semistructured clinical interviews and further confirmed using the clinical charts available for each patient. Patients were also

subdivided into two subgroups: with $DUI \leq 1$ year and with $DUI > 1$ year. Clinical assessment was done at baseline and after 8-weeks of treatment by administration of the Hamilton Rating Scale for Anxiety (HAM-A) (Guy 1976), the Clinical Global Impression rating scale (CGI) (severity item) (Guy 1976), and by evaluation of the number of panic attacks/week.

The main baseline demographic and clinical variables were calculated and compared between the two subgroups of patients (chi-square test or t-test for independent samples). The treatment efficacy and the difference between the two patient subgroups were evaluated using analysis of variance (ANOVAs) with repeated measures. In these analyses the HAM-A score, CGI score (impairment item), and number of panic attacks/week were the dependent variables.

Results

The main demographic and baseline clinical variables in the two subgroups of patients are summarized in Table 1. Patients with $DUI \leq 1$ year and patients with $DUI > 1$ year did not differ with respect to baseline clinical characteristics, including FH for anxiety or mood disorders in first degree relatives.

The clinical assessment after 8-weeks treatment with serotonergic antidepressants (venlafaxine, $n = 6$, mean 100 ± 38.7 mg/day; sertraline $n = 34$, mean 88.9 ± 26.9 mg/day; clomipramine $n = 9$, mean 86.1 ± 13.2 mg/day; paroxetine $n = 43$, mean 27.0 ± 8.3 mg/day; citalopram $n = 1$, 20 mg/day; fluoxetine $n = 3$, mean 40 ± 20 mg/day) showed a significant improvement in the whole sample, with no differences

Table 1 Baseline demographic and clinical characteristics in the whole sample and in the two subsamples defined by the duration of untreated illness (DUI)

Variables	Total (N = 96)	DUI ≤ 1 year (N = 32)	DUI > 1 year (N = 64)
Gender	26 M, 70 F	12 M, 20 F	14 M, 50 F
Age	40.14 (13.05)	35.6 (12.4)	42.5 (12.8)
Age at onset	32.26 (12.75)	34.00 (11.12)	31.39 (13.49)
Panic attacks/week	3.86 (2.16)	3.44 (1.90)	4.08 (2.26)
Positive FH for anxiety disorders	34	14	20
Positive FH for mood disorders	12	5	7
HAM-A baseline	19.90 (3.56)	19.22 (3.65)	20.23 (3.50)
CGI baseline (severity)	3.76 (0.83)	3.59 (0.91)	3.84 (0.78)

NOTE: SDs for continuous variables are shown in parentheses.

Abbreviations: CGI, Clinical Global Impression Scale; DUI, duration of illness; FH, family history in first degree relatives; HAM-A, Hamilton Rating Scale for Anxiety.

between patients with $\text{DUI} \leq 1$ year and patients with $\text{DUI} > 1$ year on the HAM-A total score (time effect: $F = 306.314$, $p < 0.00001$; group effect: $F = 3.127$, $p = 0.08$; time $\times$ group effect: $F = 0.334$, $p > 0.50$), on the number of panic attacks/week (time effect: $F = 156.457$, $p < 0.00001$; group effect: $F = 1.525$, $p > 0.020$; time $\times$ group effect: $F = 0.992$, $p > 0.30$), and on the CGI improvement item score (time effect: $F = 244.314$, $p < 0.00001$; group effect: $F = 3.304$, $p > 0.07$; time $\times$ group effect: $F = 0.127$, $p > 0.70$).

Patients with $\text{DUI} > 1$ year had a higher frequency of comorbid MDD with onset later than PD (chi-square = 7.518, $\text{dF} = 1$, $p = 0.006$) than patients with $\text{DUI} \leq 1$ year. These results did not change when we categorized patients according to gender, diagnostic subtype (presence/absence of agoraphobia), or presence/absence of positive FH for anxiety or mood disorders in first degree relatives.

Discussion

The results from this study do not appear to confirm that a longer DUI is a predictor of poorer response to pharmacotherapy, as it has been reported in previous studies (Slaap and den Boer 2001).

On the other hand, in this sample, PD patients with $\text{DUI} > 1$ year had a course complicated by the occurrence of comorbid major depression (44%) more often than PD patients with $\text{DUI} \leq 1$ year (31%). According to the literature, MDD is highly comorbid with anxiety disorders, which commonly have earlier onset and represent a significant risk factor for the development of depression itself (Hettema et al 2003; Bittner et al 2004). The association between a delay in the treatment of PD and the development of depressive episodes has been suggested by previous studies (Scheibe et al 1997; Katscing et al 1998; Shinoda et al 1999). The exact nature of this association and the pathogenetic mechanism underlying the comorbidity between PD and MDD are still obscure. The presence of common biological characteristics between the two clinical conditions (eg, alterations in the hypothalamic-pituitary-adrenal axis function, in serotonergic neurotransmission, and in growth hormone response to challenges) suggests some shared biological susceptibility (Johnson et al 1995).

In any case, the results from this preliminary naturalistic study suggest that early PD diagnosis and treatment may positively affect the risk of developing MDD. In addition, preventing the development of MDD in PD patients by early pharmacological treatment may have important clinical implications. As an example, high rates of suicide attempts or suicidal behavior have been observed in PD patients with

comorbid depression (Goodwin et al 2001), and early antipanic treatment may be a critical prevention strategy.

Limitations of this study are represented by the relatively small sample, the naturalistic design, and the relatively short follow-up. Future research will consider larger samples, controlled treatments, and longer follow-up.

References

- Altamura AC, Bassetti R, Sassella F, et al. 2001. Duration of untreated psychosis as predictor outcome in first-episode schizophrenia: a retrospective study. *Schizophr Res*, 52(1–2):29–36.
- Bittner A, Goodwin RD, Wittchen HU, et al. 2004. What characteristics of primary anxiety disorders predict subsequent major depressive disorder? *J Clin Psychiatry*, 65:618–26.
- Carpiniello B, Baita A, Carta MG, et al. 2002. Clinical and psychosocial outcome of patients affected by panic disorder with or without agoraphobia: results from a naturalistic follow-up study. *Eur Psychiatry*, 17:394–8.
- Craig TJ, Bromet EJ, Fennig S, et al. 2000. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? *Am J Psychiatry*, 157:60–6.
- Dannon PN, Iancu I, Cohen A, et al. 2004. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. *BMC Psychiatry*, 4:16.
- Diler RS, Birmaher B, Brent DA, et al. 2004. Phenomenology of panic disorder in youth. *Depress Anxiety*, 20:39–43.
- Eaton WW, Kessler RC, Wittchen H, et al. 1994. Panic and panic disorder in United States. *Am J Psychiatry*, 151:413–20.
- Goodwin R, Olsson M, Feder A, et al. 2001. Panic and suicidal ideation in primary care. *Depress Anxiety*, 14:244–6.
- Guy W. 1976. ECDEU Assessment manual for psychopharmacology. Revised. Publication nr (ADM). Bethesda: DHEW. p 76–338.
- Hettema JM, Prescott CA, Kendler KS. 2003. The effects of anxiety, substance use and conduct disorders on risk of major depressive disorder. *Psychol Med*, 33:1423–32.
- Johnson MR, Lydiard RB, Ballenger JC. 1995. Panic disorder: pathophysiology and drug treatment. *Drugs*, 49:328–44.
- Katscing H, Amering M. 1998. The long-term course of panic disorder and its predictors. *J Clin Psychopharmacol*, 18(6 Suppl 2):6–11.
- Markowitz JS, Weissman MM, Queller R, et al. 1989. Quality of life in panic disorder. *Arch Gen Psychiatry*, 46:984–92.
- Mundo E, Salvadori D, Bassetti R, et al. 2002. Duration of untreated illness and clinical course in bipolar disorder. Presented at 155th Meeting of the American Psychiatric Association, Philadelphia (PA); 2002 May 18–23.
- Pollack MH, Rapaport MH, Clary CM, et al. 2000. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. *J Clin Psychiatry*, 61:922–7.
- Scheibe G, Albus M. 1997. Predictors and outcome in panic disorder: a 2-year prospective follow-up study. *Psychopathology*, 30:177–84.
- Shinoda N, Kodama K, Sakamoto T, et al. 1999. Predictors of 1-year outcome for patients with panic disorder. *Compr Psychiatry*, 40:39–43.
- Slaap BR, den Boer JA. 2001. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. *Depress Anxiety*, 14:112–22.
- Starcevic V, Uhlenhuth EH, Kellner R, et al. 1993. Comorbidity in panic disorder. Chronology of appearance and pathogenic comorbidity. *Psychiatry Res*, 46:285–93.
- Westenberg HG, Liebowitz MR. 2004. Overview of panic and social anxiety disorders. *J Clin Psychiatry*, 65:22–6.

